Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Gegenanzeigen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.3 · PDF-Seite 4
HOS-086138 · Präparat HOS-083284
Concomitant medicinal product levels increased or decreased
1-Adrenoreceptor Alfuzosin Increased plasma concentrations of alfuzosin
Antagonist which may lead to severe hypotension (see
section 4.5).
Analgesics Pethidine, Increased plasma concentrations of
propoxyphene norpethidine and propoxyphene. Thereby,
increasing the risk of serious respiratory
depression or haematologic abnormalities, or
other serious adverse effects from these agents.
Antianginal Ranolazine Increased plasma concentrations of ranolazine
which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Anticancer Neratinib Increased plasma concentrations of neratinib
which may increase the potential for serious
and/or life-threatening reactions including
hepatotoxicity (see section 4.5).
Venetoclax Increased plasma concentrations of venetoclax.
Increased risk of tumor lysis syndrome at the
dose initiation and during the dose-titration
phase (see section 4.5).
Antiarrhythmics Amiodarone, bepridil, Increased plasma concentrations of amiodarone,
dronedarone, bepridil, dronedarone, encainide, flecanide,
encainide, flecanide, propafenone, quinidine. Thereby, increasing the
propafenone, quinidine risk of arrhythmias or other serious adverse
reactions from these agents.
Antibiotic Fusidic Acid Increased plasma concentrations of fusidic acid
and ritonavir.
Anti-gout Colchicine Potential for serious and/or life-threatening
reactions in patients with renal and/or hepatic
impairment (see sections 4.4 and 4.5).
Antihistamines Astemizole, Increased plasma concentrations of astemizole
terfenadine and terfenadine. Thereby, increasing the risk of
serious arrhythmias from these agents.
Antipsychotics/ Lurasidone Increased plasma concentrations of lurasidone
Neuroleptics which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Clozapine, pimozide Increased plasma concentrations of clozapine
and pimozide. Thereby, increasing the risk of
serious haematologic abnormalities, or other
serious adverse effects from these agents.
Quetiapine Increased plasma concentrations of quetiapine
which may lead to coma. The concomitant
administration with quetiapine is
contraindicated (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propoxyphene (HOS-086140) quetiapine (HOS-086150) encainide (HOS-086145) alfuzosin (HOS-086139) propafenone (HOS-084530) dronedarone (HOS-086144) fusidic acid (HOS-086146) bepridil (HOS-085612) quinidine (HOS-085593) neratinib (HOS-086142) venetoclax (HOS-086143) lead (HOS-085592) pimozide (HOS-085600) colchicine (HOS-086147) astemizole (HOS-085608) clozapine (HOS-086149) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ranolazine (HOS-086141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage f9fe97979894eedcce9660008265f9fc818cdb3984974bb2555b6c5e5869e4e5 · Zeichen 902–5292 im Abschnitt
Gegenanzeigen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.3 · PDF-Seite 4
HOS-114797 · Präparat HOS-094169
Co-administration of Aptivus with low dose ritonavir, with active substances that are highly dependent
on CYP3A for clearance, and for which elevated plasma concentrations are associated with serious
and/or life-threatening events. These active substances include antiarrhythmics (such as amiodarone,
bepridil, quinidine), antihistamines (such as astemizole, terfenadine), ergot derivatives (such as
dihydroergotamine, ergonovine, ergotamine, methylergonovine), gastrointestinal motility agents (such
as cisapride), antipsychotics (such as pimozide, sertindole, quetiapine, lurasidone), sedatives/hypnotics
(such as orally administered midazolam and triazolam) and HMG-CoA reductase inhibitors (such as
simvastatin and lovastatin) (see section 4.5). Also the use of the alpha-1 adrenoceptor antagonist
alfuzosin, and sildenafil when used for the treatment of pulmonary arterial hypertension. In addition,
co-administration of Aptivus with low dose ritonavir, and medicinal products that are highly
dependent on CYP2D6 for clearance, such as the antiarrhythmics flecainide, propafenone and
metoprolol given in heart failure (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) quetiapine (HOS-086150) alfuzosin (HOS-086139) methylergonovine (HOS-086155) propafenone (HOS-084530) cisapride (HOS-085610) lovastatin (HOS-086157) flecainide (HOS-086203) bepridil (HOS-085612) simvastatin (HOS-086158) quinidine (HOS-085593) pimozide (HOS-085600) astemizole (HOS-085608) sildenafil (HOS-086162) ergotamine (HOS-086154) ritonavir (HOS-084521) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ergonovine (HOS-086153) metoprolol (HOS-090094) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 899ebcf3829943bae5ad39416161803c04f5d7f21f78b5a86a8cc0fb492896e8 · Zeichen 519–1660 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 14–15
HOS-116357 · Präparat HOS-094447
14
HIV Protease inhibitors (PIs) - with co-administration of low dose ritonavir†
Lopinavir/ritonavir lopinavir AUC ↑ 9% Due to a decrease in the exposure
400/100 mg twice daily lopinavir Cmin ↑ 23% (AUC) of darunavir by 40%,
lopinavir Cmax ↓ 2% appropriate doses of the
darunavir AUC ↓ 38% ‡ combination have not been
darunavir Cmin ↓ 51% ‡ established. Hence, concomitant
‡ use of boosted PREZISTA and the
darunavir Cmax ↓ 21%
Lopinavir/ritonavir combination product
lopinavir AUC ↔
533/133.3 mg twice daily lopinavir/ritonavir is
lopinavir Cmin ↑ 13% contraindicated (see section 4.3).
lopinavir Cmax ↑ 11%
darunavir AUC ↓ 41%
darunavir Cmin ↓ 55%
darunavir Cmax ↓ 21%
‡
based upon non dose normalised values
CCR5 ANTAGONIST
Maraviroc maraviroc AUC ↑ 305% The maraviroc dose should be
150 mg twice dailymaraviroc Cmin ND 150 mg twice daily when
maraviroc Cmax ↑ 129% co-administered with boosted
darunavir, ritonavir concentrations were PREZISTA.
consistent with historical data
α1-ADRENORECEPTOR ANTAGONIST
Alfuzosin Based on theoretical considerations Co-administration of boosted
PREZISTA is expected to increase PREZISTA and alfuzosin is
alfuzosin plasma concentrations. contraindicated (see section 4.3).
(CYP3A inhibition)
ANAESTHETIC
Alfentanil Not studied. The metabolism of alfentanil The concomitant use with boosted
is mediated via CYP3A, and may as such PREZISTA may require to lower
be inhibited by boosted PREZISTA. the dose of alfentanil and requires
monitoring for risks of prolonged
or delayed respiratory depression.
ANTIANGINA/ANTIARRHYTHMIC
Disopyramide Not studied. Boosted PREZISTA is Caution is warranted and
Flecainide expected to increase these antiarrhythmic therapeutic concentration
Lidocaine (systemic) plasma concentrations. monitoring, if available, is
Mexiletine (CYP3A and/or CYP2D6 inhibition) recommended for these
Propafenone antiarrhythmics when
co-administered with boosted
PREZISTA.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) alfuzosin (HOS-086139) lopinavir (HOS-086269) propafenone (HOS-084530) protease (HOS-085623) flecainide (HOS-086203) lidocaine (HOS-108866) mexiletine (HOS-086341) disopyramide (HOS-085595) maraviroc (HOS-086186) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 79aee1bbebf74d1fc7eeb1f64d47f744ae971edc2caad3984bd946f3f467a703 · Zeichen 24118–27577 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12–13
HOS-134488 · Präparat HOS-097580
12
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Medicinal products by Interaction Geometric mean change Recommendations concerning co-
therapeutic areas (%) administration
Alfuzosin Based on theoretical considerations Co-administration of darunavir with
darunavir is expected to increase low dose ritonavir and alfuzosin is
alfuzosin plasma concentrations. contraindicated (see section 4.3).
(CYP3A inhibition)
ANAESTHETIC
Alfentanil Not studied. The metabolism of The concomitant use with darunavir
alfentanil is mediated via CYP3A, and and low dose ritonavir may require
may as such be inhibited by darunavir to lower the dose of alfentanil and
co-administered with low dose requires monitoring for risks of
ritonavir. prolonged or delayed respiratory
depression.
ANTIANGINA/ANTIARRHYTHMIC
Disopyramide Not studied. Darunavir is expected to Caution is warranted and
Flecainide increase these antiarrhythmic plasma therapeutic concentration
Lidocaine concentrations. monitoring, if available, is
(systemic) (CYP3A and/or CYP2D6 inhibition) recommended for these
Mexiletine antiarrhythmics when co-
Propafenone administered with darunavir with
low dose ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) alfuzosin (HOS-086139) propafenone (HOS-084530) flecainide (HOS-086203) lidocaine (HOS-108866) mexiletine (HOS-086341) disopyramide (HOS-085595) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 9518a303c5be83b8c623da21f0ef8178c9138853ea1049de3dcd627347157795 · Zeichen 19313–21059 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 400 mg film-coated tablets Darunavir Viatris 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 53–54
HOS-134613 · Präparat HOS-097580
53
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
Medicinal products by Interaction Recommendations concerning co-
therapeutic areas Geometric mean change (%) administration
HIV Protease inhibitors (PIs) - with co-administration of low dose ritonavir†
Lopinavir/ritonavir 400/100 lopinavir AUC ↑ 9% Due to a decrease in the exposure
mg twice daily lopinavir Cmin ↑ 23% (AUC) of darunavir by 40%,
lopinavir Cmax ↓ 2% appropriate doses of the combination
have not been established. Hence,
darunavir AUC ↓ 38%‡ concomitant use of boosted darunavir
darunavir Cmin ↓ 51%‡ and the combination product
darunavir Cmax ↓ 21%‡ lopinavir/ritonavir is contraindicated
Lopinavir/ritonavir lopinavir AUC ↔ (see section 4.3).
533/133.3 mg twice daily lopinavir Cmin ↑ 13%
lopinavir Cmax ↑ 11%
darunavir AUC ↓ 41%
darunavir Cmin ↓ 55%
darunavir Cmax ↓ 21%
‡
based upon non dose normalised
values
CCR5 ANTAGONIST
Maraviroc maraviroc AUC ↑ 305% The maraviroc dose should be 150
150 mg twice daily maraviroc Cmin ND mg twice daily when co-administered
maraviroc Cmax ↑ 129% with boosted darunavir.
darunavir, ritonavir concentrations
were consistent with historical data
α1-ADRENORECEPTOR ANTAGONIST
Alfuzosin Based on theoretical considerations Co-administration of boosted
darunavir is expected to increase darunavir and alfuzosin is
alfuzosin plasma concentrations. contraindicated (see section 4.3).
(CYP3A inhibition)
ANAESTHETIC
Alfentanil Not studied. The metabolism of The concomitant use with boosted
alfentanil is mediated via CYP3A, darunavir may require to lower the
and may as such be inhibited by dose of alfentanil and requires
boosted darunavir. monitoring for risks of prolonged or
delayed respiratory depression.
ANTIANGINA/ANTIARRHYTHMIC
Disopyramide Not studied. Boosted darunavir is Caution is warranted and ther apeutic
Flecainide expected to increase these concentration monitoring, if
Lidocaine (systemic) antiarrhythmic plasma available, is recommended for these
Mexiletine concentrations. antiarrhythmics when co-
Propafenone (CYP3A and/or CYP2D6 administered with boosted darunavir.
inhibition)
Amiodarone Bepridil Co-administration of boosted
Dronedarone Ivabradine darunavir and amiodarone, bepridil,
Quinidine Ranolazine dronedarone, ivabradine, quinidine,
or ranolazine is contraindicated (see
section 4.3).
Digoxin digoxin AUC ↑ 61% Given that digoxin has a narrow
0.4 mg single dose digoxin Cmin ND therapeutic index, it is recommended
digoxin Cmax ↑ 29% that the lowest possible dose of
(↑ digoxin from probable inhibition digoxin should initially be prescribed
of P-gp) in case digoxin is given to patients on
boosted darunavir therapy. The
digoxin dose should be carefully
titrated to obtain the desired clinical
effect while assessing the overall
clinical state of the subject.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) alfuzosin (HOS-086139) lopinavir (HOS-086269) propafenone (HOS-084530) dronedarone (HOS-086144) protease (HOS-085623) flecainide (HOS-086203) lidocaine (HOS-108866) mexiletine (HOS-086341) bepridil (HOS-085612) quinidine (HOS-085593) digoxin (HOS-086172) disopyramide (HOS-085595) maraviroc (HOS-086186) ivabradine (HOS-109426) ritonavir (HOS-084521) amiodarone (HOS-085596) ranolazine (HOS-086141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 737ba554b4078e65ecf09cd520335cc5df12785cb4f30673452d55d887588655 · Zeichen 22720–27726 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.